Joe Payne, President and CEO, highlighted heightened interest in the company's mRNA therapeutics pipeline, pointing to forthcoming clinical data for both the ARCT-032 cystic fibrosis program and the ...

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 67.09% and 3.10%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Arcturus Therapeutics (ARCT) on Monday reported a loss of $14.1 million in its first quarter. On a per-share basis, the San Diego-based company said it had a loss of ...

Detailed price information for Denali Therapeutics Inc (DNLI-Q) from The Globe and Mail including charting and trades.

Smaller-scale trades involved Pacific Biosciences of California Inc (NASDAQ: PACB) and 10X Genomics Inc (NASDAQ: TXG ), with ARK purchasing 194,298 and 18,177 shares respectively, totaling $213,727 ...